NAVLIN Daily NewsCheckout Today’s News
Germany’s Federal Ministry of Health (BMG) has announced that a new expert panel is developing proposals for a legally compliant framework for the "location clause," which follows a mandate from the parliamentary process surrounding the reform to stabilize the contribution rates in the statutory health insurance (GKV-BStabG) from 2027From January 1, 2027, manufacturers of patent-protected medicines will, in principle, face a total discount of 15.5% under the reform. This comprises the existing 7% manufacturer discount and an additional 8.5% discount. Meanwhile, the location clause is also scheduled to take effect from January 1, 2027, and is intended to provide exceptions to the additional burden where companies make investments that benefit Germany as a pharmaceutical locationIn addition, the expert committee is to develop proposals for measures to improve incentives for investment in research, development, and production of pharmaceuticals in Germany
The trade association for research-based pharmaceutical companies operating in Sweden (Lif) has called for a Most Favored Nation (MFN) task force, similar to the one set up in neighboring DenmarkThe group warns that the U.S. MFN can have major consequences for Sweden, which is a small country with relatively low drug prices, adding: “There is a risk that new drugs will be launched later or not at all, while the conditions for clinical trials and investments deteriorate”Earlier this year, Denmark set up the MFN task force to examine the potential consequences of the policy, and recently held its first meeting
The U.S. administration expanded its Most Favored Nation (MFN) drug pricing initiative to 26 manufacturers covering an estimated 89% of the branded drug market, with the inclusion of nine new companies: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCBThe latest agreements bring several midsized and specialty-focused manufacturers into the programOtherwise, the deal framework appears similar to earlier agreements and is centered around providing MFN pricing on existing medicines through Medicaid (by participating in the GENEROUS Model), extending MFN pricing to new product launches, and supporting domestic pharmaceutical manufacturing and supply chain initiatives
Last week, NAVLIN Daily brought you key market access developments from across the globeIn the U.S., President Donald Trump is expected to announce new MFN drug pricing deals in the coming days. Reportedly, the deals will include commitments to offer MFN pricing to state Medicaid programs, potentially increasing manufacturer participation in CMS’ voluntary GENEROUS modelMeanwhile, the CDA issued new guidance on using AI-generated real-world evidence in HTA submissions, and China updated its Disease-Based Payment reimbursement scheme to include 158 primary care conditions
NICE has confirmed it is adopting the UK EQ-5D-5L value set, following a consultation The EQ-5D-5L value set reflects more recent research into societal preferences as a basis for the QALY calculations that underpin NICE’s cost-effectiveness assessmentsAn ABPI impact assessment of 71 technology appraisals found that cancer treatments extending life tend to become more cost-effective under the new value set, while treatments that improve quality of life without extending it may become less so, with implications for patient access
The U.S. White House is expected to announce new Most Favored Nation (MFN) drug pricing agreements with several midsized biotechnology companies on Monday, according to reports from BloombergThe outlet notes that the deals will include commitments to offer MFN pricing to state Medicaid programs, potentially increasing manufacturer participation in CMS’ voluntary GENEROUS modelThe announcements will be closely watched for signs that the administration has adjusted its MFN approach to address concerns from midsized drugmakers, many of which have been reluctant to participate in existing pricing initiatives
China’s former NHSA official, Xiong Xianjun, said the “impossible trio” – or the infeasible coexistence of high-priced innovative drugs, insurance fund sustainability, and patient access – is a mythHe sees national insurance price negotiations in terms of basic economics, with win-win transactions possible even for expensive new drugsThe former director added that the Commercial Insurance Innovative Drug List helps innovative drugs enter hospitals, but full implementation requires the development of a seamless system to tie public and private insurance and expand commercial insurance premium pools
The U.S. Department of Health and Human Services (HHS) recently published a Request for Information (RFI) soliciting public feedback on federal vaccine recommendationsThe agency is looking for comments on the categories used in federal vaccine recommendations, including routine (universal), risk-based, and shared clinical decision makingComments in response to the RFI must be submitted by September 20, 2026
Last week, NAVLIN Daily brought you key market access developments from across the globe In the U.S., nine major PBMs moved to integrate TrumpRx cash prices into benefit tools, while a new BLS report found that prescription drug prices fell 3.1% from July 2025 to July 2026, their sharpest annual decline in more than 60 years In Japan, a health ministry-funded research group broadly agreed on its technical review of the CEA system
Following China's latest VBP round in July, PhIRDA reports that the system now favors big players more heavily. Hospitals can specify brand preferences, and revival bids can benefit original brands and leading genericsAt the same time, some manufacturers continue to cut prices by 80% to stay competitive, disrupting markets and straining anti-involution effortsIncreasingly complicated rules, with anchors and weight systems, aim to balance needs but risk overshadowing core VBP goals, leaving policymakers with lingering hurdles
650+
+99%
<24
4,000+
24x7
99.5%
